12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CF101: Interim Phase II/III data

Interim data from 103 patients with moderate to severe plaque psoriasis in a double-blind, Israeli Phase II/III trial showed that twice-daily 2 mg oral CF101 produced a PGA response rate of 53% (p=0.0153 compared to the twice-daily 1 mg dose of CF101) and a PASI 75 response rate of 41% at week 24....

Read the full 242 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >